Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06025396 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of TMP-301 in Healthy Subjects
A Phase 1 study, sponsored by Tempero Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06025396 is a Phase 1 study that has completed, run by Tempero Bio. The registered enrollment target is 30 participants.
The verdict
NCT06025396, a Phase 1 study, has completed, sponsored by Tempero Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
Interventions
- DRUG Placebo
- DRUG Cohort 1 - TMP-301
- DRUG Cohort 2 - TMP-301
- DRUG Cohort 3 - TMP-301
- DRUG Cohort 4 - TMP-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2024-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06025396
The ClinicalTrials.gov registry entry for NCT06025396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tempero Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06025396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06025396 about?
NCT06025396 is a clinical study titled "Multiple Ascending Dose Study of TMP-301 in Healthy Subjects". A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
What is the current status of trial NCT06025396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-01-06. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT06025396?
The interventions under investigation include: Placebo (DRUG), Cohort 1 - TMP-301 (DRUG), Cohort 2 - TMP-301 (DRUG), Cohort 3 - TMP-301 (DRUG), Cohort 4 - TMP-301 (DRUG).
Who is sponsoring clinical trial NCT06025396?
This trial is sponsored by Tempero Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.